Amarin Corp Plc (AMRN)

[SovereignNinja5]

This is why a level B meeting with FDA under PDUFA is so important. Berg should have been instructed to do them by Sarissa considering this is all Sarissa’s plan at increasing value. Proper lifecycle management of a patent is why the FDA regs are written. A SNDA path using 505(b) (2) exists for a reason. Why 505(b)(2) Is the Chosen Path for LR-EtEPA
1.  LR-EtEPA is not a new chemical entity

The active ingredient is ethyl eicosapentaenoic acid (EtEPA / icosapent ethyl) — the same as in Vascepa. The innovation is in the formulation (phospholipids + emulsifiers to promote lymphatic uptake), not the molecule itself. A 505(b)(1) application would be inappropriate and inefficient for a reformulation.
2.  FDA explicitly allows reliance on existing outcomes data

Under 505(b)(2), the applicant may rely on the FDA’s prior determination that icosapent ethyl is safe and effective for the CVRR indication (established in REDUCE-IT). The sponsor must provide bridging data showing that the new formulation delivers comparable or improved systemic exposure without introducing new safety issues. Amarin has already presented mechanistic and PK data supporting lymphatic absorption benefits — this is exactly the type of bridging information the FDA accepts in 505(b)(2) reformulation applications.
3.  Avoiding another large outcomes trial

The poster correctly notes that the FDA required REDUCE-IT (n=8,179, ~5 years) before granting the CVRR indication. Repeating a similar trial for a reformulation would be extremely costly and time-consuming. 505(b)(2) avoids this by allowing reliance on the original trial data, provided the reformulation does not meaningfully alter the risk-benefit profile.
4.  Precedent supports this approach

Numerous reformulations of approved drugs have been approved via 505(b)(2) without repeating large outcomes trials, including extended-release versions, new delivery systems, and combination products. The FDA’s guidance document “Applications Covered by Section 505(b)(2)” (December 1999, reaffirmed in later documents) explicitly states that bridging studies are often sufficient when the active ingredient and indication remain the same.
5.  Commercial and patent strategy alignment

Using 505(b)(2) enables faster market entry (projected late 2026–early 2027) and allows Amarin to list the new composition/method-of-use patents in the Orange Book upon issuance, extending effective exclusivity without needing to re-prove the entire CVRR benefit in a new large trial.
In summary, the 505(b)(2) pathway is the correct, efficient, and FDA-accepted route for LR-EtEPA precisely because it is a reformulation of an approved active ingredient with established long-term outcomes data. A 505(b)(1) application would be unnecessary, prohibitively expensive, and contrary to regulatory precedent and guidance. The poster’s concern about a possible additional study is valid — the FDA could request limited clinical data if bridging studies raise questions — but it would almost certainly be far smaller and shorter than REDUCE-IT, if required at all.